The Trust Layer for Market Analysts

Novo Nordisk is currently navigating a challenging GLP-1 market due to competition from compounders and Eli Lilly, whose treatments are showing superior performance. This has led to a significant decline in Novo Nordisk's stock, currently trading at $48.46, close to its 52-week low of $45.00. Despite these market headwinds, the company's obesity care segment reported a 41% sales increase in the most recent quarter, with US operations growing 24% and international operations 83%. Wegovy sales alone reached approximately DKK 20 billion, representing a 168% year-over-year growth. Novo Nordisk maintains a dominant 68% market share in the combined diabetes and obesity GLP-1 international market, with Ozempic launched in around 80 countries. While weekly Ozempic prescriptions in the US saw a 20,000 unit decrease from Q2 to Q3 2025, the overall GLP-1 diabetes market grew 10% in Q3 2025 compared to Q3 2024. The company is investing in commercial activities, including direct-to-patient offerings and collaborations with GoodRx and Costco, and is working with the US administration for broader treatment accessibility. A key future catalyst is the anticipated regulatory decision for the oral Wegovy pill later this year, with a planned launch in early 2026. This would make Novo Nordisk the first to market with an oral obesity treatment. The analyst's fair value calculation for Novo Nordisk is $67.73, suggesting a buying opportunity for long-term investors despite the current bearish market trend, with a calculated failure bound at $40.00.